{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:31:27Z","timestamp":1794108687383,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["M3\/6"],"award-info":[{"award-number":["M3\/6"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["POR FESR 2014\/2020 \u2013 Progetto Campania Onco-Terapie CUP: B61G18000470007"],"award-info":[{"award-number":["POR FESR 2014\/2020 \u2013 Progetto Campania Onco-Terapie CUP: B61G18000470007"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triple negative breast cancer (TNBC) is an aggressive disease characterized by high risk of relapse and development of resistance to different chemotherapy agents. Several targeted therapies have been investigated in TNBC with modest results in clinical trials. Among these, PI3K\/AKT inhibitors have been evaluated in addition to standard therapies, yielding conflicting results and making attempts on elucidating inherent mechanisms of resistance of great interest. Increasing evidences suggest that PI3K\/AKT inhibitors can induce autophagy in different cancers. Autophagy represents a supposed mechanism of drug-resistance in aggressive tumors, like TNBC. We, therefore, investigated if two PI3K\/AKT inhibitors, ipatasertib and taselisib, could induce autophagy in breast cancer models, and whether chloroquine (CQ), a well known autophagy inhibitor, could potentiate ipatasertib and taselisib anti-cancer effect in combination with conventional chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The induction of autophagy after ipatasertib and taselisib treatment was evaluated in MDAMB231, MDAM468, MCF7, SKBR3 and MDAB361 breast cancer cell lines by assaying LC3-I conversion to LC3-II through immunoblotting and immunofluorescence. Other autophagy-markers as p62\/SQSTM1 and ATG5 were evaluated by immunoblotting. Synergistic antiproliferative effect of double and triple combinations of ipatasertib\/taselisib plus CQ and\/or paclitaxel were evaluated by SRB assay and clonogenic assay. Anti-apoptotic effect of double combination of ipatasertib\/taselisib plus CQ was evaluated by increased cleaved-PARP by immunoblot and by Annexin V- flow cytometric analysis. In vivo experiments were performed on xenograft model of MDAMB231 in NOD\/SCID mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results suggested that ipatasertib and taselisib induce increased autophagy signaling in different breast cancer models. This effect was particularly evident in PI3K\/AKT resistant TNBC cells, where the inhibition of autophagy by CQ potentiates the therapeutic effect of PI3K\/AKT inhibitors in vitro and in vivo TNBC models, synergizing with taxane-based chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These data suggest that inhibition of authophagy with CQ could overcome mechanism of drug resistance to PI3K\/AKT inhibitors plus paclitaxel in TNBC making the evaluation of such combinations in clinical trials warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03462-z","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T09:03:12Z","timestamp":1656320592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Inhibition of autophagy by chloroquine prevents resistance to PI3K\/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models"],"prefix":"10.1186","volume":"20","author":[{"given":"Stefania","family":"Cocco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-2937","authenticated-orcid":false,"given":"Alessandra","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Sisalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"3462_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041199","author":"S Sridharan","year":"2020","unstructured":"Sridharan S, Basu A. Distinct roles of mTOR targets S6K1 and S6K2 in breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21041199.","journal-title":"Int J Mol Sci"},{"key":"3462_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41598-020-58438-0","volume":"10","author":"TH Turner","year":"2020","unstructured":"Turner TH, Alzubi MA, Harrell JC. Identification of synergistic drug combinations using breast cancer patient-derived xenografts. Sci Rep. 2020;10:1493.","journal-title":"Sci Rep"},{"key":"3462_CR3","doi-asserted-by":"publisher","first-page":"117955491986848","DOI":"10.1177\/1179554919868482","volume":"13","author":"CH Saravia","year":"2019","unstructured":"Saravia CH, Flores C, Schwarz LJ, Bravo L, Zavaleta J, Araujo J, et al. Patterns of mutation enrichment in metastatic triple-negative breast cancer. Clin Med Insights Oncol. 2019;13:1179554919868482.","journal-title":"Clin Med Insights Oncol"},{"key":"3462_CR4","first-page":"34206","volume":"6","author":"S Pamarthy","year":"2015","unstructured":"Pamarthy S, Jaiswal MK, Kulshreshtha A, Katara GK, Gilman-Sachs A, Beaman KD. The Vacuolar ATPase a2-subunit regulates notch signaling in triple-negative breast cancer cells. Oncotarget Impact Journals LLC. 2015;6:34206\u201320.","journal-title":"Oncotarget Impact Journals LLC"},{"issue":"19","key":"3462_CR5","first-page":"4285","volume":"57","author":"M O\u2019Connor","year":"1997","unstructured":"O\u2019Connor M, Jackman J, Bae I, Myers G. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57(19):4285\u2013300.","journal-title":"Cancer Res"},{"key":"3462_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","volume":"3","author":"EA O\u2019Reilly","year":"2015","unstructured":"O\u2019Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, et al. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257\u201375.","journal-title":"BBA Clin"},{"key":"3462_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/028418600750013096","volume":"39","author":"J Overgaard","year":"2000","unstructured":"Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000;39:327\u201333.","journal-title":"Acta Oncol"},{"key":"3462_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134579","author":"S Cocco","year":"2020","unstructured":"Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21134579.","journal-title":"Int J Mol Sci"},{"key":"3462_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017;170:605\u201335.","journal-title":"Cell"},{"key":"3462_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7\u201324.","journal-title":"Nat Rev Cancer"},{"key":"3462_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960\u201376.","journal-title":"Cell"},{"key":"3462_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"3462_CR13","doi-asserted-by":"publisher","first-page":"x27","DOI":"10.1093\/annonc\/mdz280","volume":"30","author":"M Brand\u00e3o","year":"2019","unstructured":"Brand\u00e3o M, Caparica R, Eiger D, de Azambuja E. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol. 2019;30:x27-42.","journal-title":"Ann Oncol"},{"key":"3462_CR14","doi-asserted-by":"crossref","unstructured":"Phase II Study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor\u2013positive advanced breast cancer | clinical cancer research. https:\/\/clincancerres.aacrjournals.org\/content\/24\/18\/4380. Accessed date Apr 7 2021","DOI":"10.1158\/1078-0432.CCR-18-0613"},{"key":"3462_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2020.10.596","volume":"32","author":"S Dent","year":"2021","unstructured":"Dent S, Cort\u00e9s J, Im Y-H, Di\u00e9ras V, Harbeck N, Krop IE, et al. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Ann Oncol. 2021;32:197\u2013207.","journal-title":"Ann Oncol"},{"key":"3462_CR16","unstructured":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet Oncology. https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(17)30450-3\/fulltext. Accessed date Apr 7 2021"},{"key":"3462_CR17","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","volume":"26","author":"BD Lehmann","year":"2020","unstructured":"Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, et al. TBCRC 032 IB\/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26:2111\u201323.","journal-title":"Clin Cancer Res"},{"issue":"suppl_4","key":"3462_CR18","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1016\/annonc\/annonc268","volume":"31","author":"N Turner","year":"2020","unstructured":"Turner N, Dent R, O'Shaughnessy J, Kim S, Isakoff S, Barrios CH, Saji S, Bondarenko I, Nowecki Z, Lian Q, Reilly S, Hinton H, Wongchenko M, Mani A, Oliveira M. Ipatasertib (IPAT) + paclitaxel (PAC) forPIK3CA\/AKT1\/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial. Ann. Oncol. 2020;31(suppl_4):S348\u201395. https:\/\/doi.org\/10.1016\/annonc\/annonc268.","journal-title":"Annals of Oncology"},{"key":"3462_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.bcp.2011.11.022","volume":"83","author":"CR Loehberg","year":"2012","unstructured":"Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, et al. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol. 2012;83:480\u20138.","journal-title":"Biochem Pharmacol"},{"key":"3462_CR20","doi-asserted-by":"publisher","first-page":"19897","DOI":"10.18632\/oncotarget.7658","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, et al. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget. 2016;7:19897\u2013909.","journal-title":"Oncotarget"},{"key":"3462_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/2211-5463.12806","volume":"10","author":"J Cai","year":"2020","unstructured":"Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, et al. The PI3K\/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio. 2020;10:535\u201345.","journal-title":"FEBS Open Bio"},{"key":"3462_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jsbmb.2018.05.006","volume":"183","author":"C Amaral","year":"2018","unstructured":"Amaral C, Augusto TV, Tavares-da-Silva E, Roleira FMF, Correia-da-Silva G, Teixeira N. Hormone-dependent breast cancer: targeting autophagy and PI3K overcomes exemestane-acquired resistance. J Steroid Biochem Mol Biol. 2018;183:51\u201361.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3462_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.7754\/Clin.Lab.2015.150423","volume":"61","author":"Y Ji","year":"2015","unstructured":"Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J. Inhibition of autophagy increases proliferation inhibition and apoptosis induced by the PI3K\/mTOR Inhibitor NVP-BEZ235 in breast cancer cells. Clin Lab. 2015;61:1043\u201351.","journal-title":"Clin Lab"},{"key":"3462_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim YC, Guan K-L. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25\u201332.","journal-title":"J Clin Invest"},{"key":"3462_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217836","author":"S Cocco","year":"2020","unstructured":"Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, et al. Targeting autophagy in breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21217836.","journal-title":"Int J Mol Sci"},{"key":"3462_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nature13939","volume":"516","author":"C Settembre","year":"2014","unstructured":"Settembre C, Ballabio A. Cell metabolism: autophagy transcribed. Nature. 2014;516:40\u20131.","journal-title":"Nature"},{"key":"3462_CR27","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/emboj.2012.32","volume":"31","author":"C Settembre","year":"2012","unstructured":"Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31:1095\u2013108.","journal-title":"EMBO J"},{"key":"3462_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3858\/emm.2012.44.2.033","volume":"44","author":"KS Choi","year":"2012","unstructured":"Choi KS. Autophagy and cancer. Exp Mol Med. 2012;44:109\u201320.","journal-title":"Exp Mol Med"},{"key":"3462_CR29","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s13277-015-3800-9","volume":"37","author":"S Chen","year":"2016","unstructured":"Chen S, Zhu X, Qiao H, Ye M, Lai X, Yu S, et al. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib. Tumour Biol. 2016;37:2321\u201331.","journal-title":"Tumour Biol"},{"key":"3462_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.devcel.2008.08.012","volume":"15","author":"F Cecconi","year":"2008","unstructured":"Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell. 2008;15:344\u201357.","journal-title":"Dev Cell"},{"key":"3462_CR31","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1172\/JCI20039","volume":"112","author":"X Qu","year":"2003","unstructured":"Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809\u201320.","journal-title":"J Clin Invest"},{"key":"3462_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/45257","volume":"402","author":"XH Liang","year":"1999","unstructured":"Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672\u20136.","journal-title":"Nature"},{"key":"3462_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20:51\u20136.","journal-title":"Curr Opin Genet Dev"},{"key":"3462_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2006.06.001","volume":"10","author":"K Degenhardt","year":"2006","unstructured":"Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51\u201364.","journal-title":"Cancer Cell"},{"key":"3462_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070965","author":"S-Y Park","year":"2019","unstructured":"Park S-Y, Choi J-H, Nam J-S. Targeting cancer stem cells in triple-negative breast cancer. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11070965.","journal-title":"Cancers (Basel)"},{"key":"3462_CR36","doi-asserted-by":"publisher","DOI":"10.2174\/1574892815666210106111012","author":"W Fong","year":"2021","unstructured":"Fong W, To KKW. Repurposing chloroquine analogs as an adjuvant cancer therapy. Recent Pat Anticancer Drug Discov. 2021. https:\/\/doi.org\/10.2174\/1574892815666210106111012.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"3462_CR37","doi-asserted-by":"crossref","unstructured":"Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, et al. 2017 Repurposing Drugs in Oncology (ReDO)\u2014chloroquine and hydroxychloroquine as anti-cancer agents. http:\/\/ecancer.org\/en\/journal\/article\/781-repurposing-drugs-in-oncology-redo-chloroquine-and-hydroxychloroquine-as-anti-cancer-agents. Accessed date Sep 25 2020","DOI":"10.3332\/ecancer.2017.781"},{"key":"3462_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.406","volume":"4","author":"F Bruzzese","year":"2013","unstructured":"Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013;4: e878.","journal-title":"Cell Death Dis"},{"key":"3462_CR39","doi-asserted-by":"publisher","first-page":"19559","DOI":"10.18632\/oncotarget.7195","volume":"7","author":"C Ciardiello","year":"2016","unstructured":"Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, et al. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget. 2016;7:19559\u201374.","journal-title":"Oncotarget"},{"key":"3462_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13046-017-0647-5","volume":"36","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, et al. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. J Exp Clin Cancer Res. 2017;36:177.","journal-title":"J Exp Clin Cancer Res"},{"key":"3462_CR41","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/1078-0432.CCR-15-2245","volume":"22","author":"ZS Zumsteg","year":"2016","unstructured":"Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, et al. Taselisib (GDC-0032), a potent \u03b2-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations. Clin Cancer Res. 2016;22:2009\u201319.","journal-title":"Clin Cancer Res"},{"key":"3462_CR42","doi-asserted-by":"publisher","first-page":"114156","DOI":"10.18632\/oncotarget.23169","volume":"8","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017;8:114156\u201372.","journal-title":"Oncotarget"},{"key":"3462_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030156","volume":"3","author":"WT Jackson","year":"2005","unstructured":"Jackson WT, Giddings TH, Taylor MP, Mulinyawe S, Rabinovitch M, Kopito RR, et al. Subversion of cellular autophagosomal machinery by RNA viruses. PLoS Biol. 2005;3: e156.","journal-title":"PLoS Biol"},{"key":"3462_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003065","volume":"3","author":"Q-B She","year":"2008","unstructured":"She Q-B, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE. 2008;3: e3065.","journal-title":"PLoS ONE"},{"key":"3462_CR45","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.1158\/1078-0432.CCR-19-0508","volume":"25","author":"RD Baird","year":"2019","unstructured":"Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, et al. POSEIDON Trial Phase 1b results: safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients. Clin Cancer Res. 2019;25:6598\u2013605.","journal-title":"Clin Cancer Res"},{"key":"3462_CR46","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yexcr.2016.07.001","volume":"346","author":"NM Jackson","year":"2016","unstructured":"Jackson NM, Ceresa BP. Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells. Exp Cell Res. 2016;346:224\u201332.","journal-title":"Exp Cell Res"},{"key":"3462_CR47","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","volume":"19","author":"J Lin","year":"2013","unstructured":"Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013;19:1760\u201372.","journal-title":"Clin Cancer Res"},{"key":"3462_CR48","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","volume":"15","author":"KP Hoeflich","year":"2009","unstructured":"Hoeflich KP, O\u2019Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15:4649\u201364.","journal-title":"Clin Cancer Res"},{"key":"3462_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fonc.2017.00293","volume":"7","author":"F Mittler","year":"2017","unstructured":"Mittler F, Obe\u00efd P, Rulina AV, Haguet V, Gidrol X, Balakirev MY. High-content monitoring of drug effects in a 3D spheroid model. Front Oncol. 2017;7:293.","journal-title":"Front Oncol"},{"key":"3462_CR50","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1158\/1078-0432.CCR-13-0978","volume":"19","author":"Y Yan","year":"2013","unstructured":"Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodr\u00edguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res. 2013;19:6976\u201386.","journal-title":"Clin Cancer Res"},{"key":"3462_CR51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132\u201341.","journal-title":"Nat Cell Biol"},{"key":"3462_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1483-7","author":"X Peng","year":"2019","unstructured":"Peng X, Wang Y, Li H, Fan J, Shen J, Yu X, et al. ATG5-mediated autophagy suppresses NF-\u03baB signaling to limit epithelial inflammatory response to kidney injury. Cell Death Dis. 2019. https:\/\/doi.org\/10.1038\/s41419-019-1483-7.","journal-title":"Cell Death Dis"},{"key":"3462_CR53","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K-J, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14:1435\u201355.","journal-title":"Autophagy"},{"key":"3462_CR54","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/j.drudis.2020.06.030","volume":"25","author":"R Chang","year":"2020","unstructured":"Chang R, Sun W-Z. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discov Today. 2020;25:1786\u201392.","journal-title":"Drug Discov Today"},{"key":"3462_CR55","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF00280130","volume":"42","author":"P Augustijns","year":"1992","unstructured":"Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42:429\u201333.","journal-title":"Eur J Clin Pharmacol"},{"key":"3462_CR56","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2217\/fon-2019-0059","volume":"15","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s J, Andr\u00e9 F, Gon\u00e7alves A, K\u00fcmmel S, Mart\u00edn M, Schmid P, et al. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019;15:1951\u201361.","journal-title":"Future Oncol"},{"key":"3462_CR57","doi-asserted-by":"crossref","unstructured":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer| science. https:\/\/science.sciencemag.org\/content\/275\/5308\/1943.full. Accessed date Apr 15 2021","DOI":"10.1126\/science.275.5308.1943"},{"key":"3462_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/1758834014530023","volume":"6","author":"E Paplomata","year":"2014","unstructured":"Paplomata E, O\u2019Regan R. The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154\u201366.","journal-title":"Ther Adv Med Oncol"},{"key":"3462_CR59","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. J Clin Oncol. 2020;38:423\u201333.","journal-title":"J Clin Oncol"},{"key":"3462_CR60","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(19)30334-1","volume":"20","author":"C Saura","year":"2019","unstructured":"Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pe\u00f1a L, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20:1226\u201338.","journal-title":"Lancet Oncol"},{"issue":"Pt 3","key":"3462_CR61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1042\/bj3330757","volume":"333","author":"NJ Hellyer","year":"1998","unstructured":"Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J. 1998;333(Pt 3):757\u201363.","journal-title":"Biochem J"},{"key":"3462_CR62","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100:8933\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3462_CR63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"IA Mayer","year":"2017","unstructured":"Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, et al. A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+\/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23:26\u201334.","journal-title":"Clin Cancer Res"},{"key":"3462_CR64","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-13-1043","volume":"13","author":"B Zhai","year":"2014","unstructured":"Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther. 2014;13:1589\u201398.","journal-title":"Mol Cancer Ther"},{"key":"3462_CR65","unstructured":"IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Abstract\u2014Europe PMC. https:\/\/europepmc.org\/article\/pmc\/pmc6148236. Accessed date Sep 28 2020."},{"key":"3462_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00326-4","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Kishikawa T, Sato T, Takeda N, Sugiura Y, Seimiya T, et al. Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Ther. 2021. https:\/\/doi.org\/10.1038\/s41417-021-00326-4.","journal-title":"Cancer Gene Ther"},{"key":"3462_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41568-019-0137-5","volume":"19","author":"S Seton-Rogers","year":"2019","unstructured":"Seton-Rogers S. Eliminating protective autophagy in KRAS-mutant cancers. Nat Rev Cancer. 2019;19:247\u2013247.","journal-title":"Nat Rev Cancer"},{"key":"3462_CR68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.trecan.2019.04.003","volume":"5","author":"H Zhao","year":"2019","unstructured":"Zhao H, Zheng B. Dual targeting of autophagy and MEK in KRAS mutant cancer. Trends Cancer. 2019;5:327\u20139.","journal-title":"Trends Cancer"},{"key":"3462_CR69","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12032-013-0475-1","volume":"30","author":"H Zhao","year":"2013","unstructured":"Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol. 2013;30:475.","journal-title":"Med Oncol"},{"key":"3462_CR70","unstructured":"ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes. Abstract\u2014Europe PMC. https:\/\/europepmc.org\/article\/med\/30563263 Accessed date 28 Sept 2020."},{"key":"3462_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00432-017-2557-5","volume":"144","author":"Z Hamurcu","year":"2018","unstructured":"Hamurcu Z, Deliba\u015f\u0131 N, Ge\u00e7ene S, \u015eener EF, D\u00f6nmez-Altunta\u015f H, \u00d6zkul Y, et al. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR\/Integrin \u03b21\/ Src signaling in triple negative breast cancer cells. J Cancer Res Clin Oncol. 2018;144:415\u201330.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3462_CR72","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1158\/0008-5472.CAN-13-3470","volume":"74","author":"P Maycotte","year":"2014","unstructured":"Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, et al. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014;74:2579.","journal-title":"Cancer Res"},{"key":"3462_CR73","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbrc.2019.09.133","volume":"520","author":"W Chen","year":"2019","unstructured":"Chen W, Bai Y, Patel C, Geng F. Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization. Biochem Biophys Res Commun. 2019;520:263\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3462_CR74","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3892\/or.2014.3095","volume":"31","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wang Q, Ma A, Li Y, Li R, Wang Y. Functional expression of TLR9 in esophageal cancer. Oncol Rep. 2014;31:2298\u2013304.","journal-title":"Oncol Rep"},{"key":"3462_CR75","doi-asserted-by":"publisher","first-page":"e31004","DOI":"10.1371\/journal.pone.0031004","volume":"7","author":"J Kim","year":"2012","unstructured":"Kim J, Yip MLR, Shen X, Li H, Hsin L-YC, Labarge S, et al. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLoS ONE. 2012;7:e31004\u2013e31004.","journal-title":"PLoS ONE"},{"key":"3462_CR76","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-019-05381-y","volume":"178","author":"A Arnaout","year":"2019","unstructured":"Arnaout A, Robertson SJ, Pond GR, Lee H, Jeong A, Ianni L, et al. A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. Breast Cancer Res Treat. 2019;178:327\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"3462_CR77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155\u201366.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03462-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03462-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03462-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T10:14:08Z","timestamp":1656324848000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03462-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3462"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03462-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental protocols for in vivo mice studies were approved by the Italian Ministry of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and approved the manuscript and consent publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"290"}}